Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Report: J & J May Pay $1.8B to Settle Risperdal Probe

By Pharmaceutical Processing | March 13, 2012

According to people familiar with the matter, Johnson & Johnson may have to increase by about $800 million its $1-billion proposal to resolve claims made by the U.S. and some states regarding the marketing of Risperdal (risperidone), Bloomberg reported Monday.

The U.S. Attorney’s office in Philadelphia negotiated a settlement of approximately $1 billion late in 2011, according to the sources, but the U.S. Department of Justice and some U.S. states involved in the suit determined that that amount was inadequate. One source indicated that the drugmaker increased its offer to $1.3 billion by March 8 and that discussions about a final amount are ongoing.

A person familiar with the case suggested that a $158-million settlement between Texas attorneys and Johnson & Johnson in a separate lawsuit over the marketing practices for Risperdal in that state increased the demands by other states and the Justice Department.

Meanwhile, one source stated that the number of U.S. states that will join final agreements between the drugmaker and the justice department over Risperdal marketing has not yet been determined. A person familiar with the issue added that the regulator expects to announce a final deal in May.

Last week, the Wall Street Journal cited sources which suggested that the justice department had rejected Johnson & Johnson’s proposed $1-billion settlement over the marketing of the antipsychotic and was seeking payment of about $1.4 billion from the company.

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE